Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications
The NCCN 2026 Annual Conference.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 29, 2026
CLO26-074: A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs).
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026
CLO26-074: A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs).
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026
Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 19, 2026
A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: September 10, 2025
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.
Journal: International journal of cancer
Published: July 17, 2025
Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment.
Journal: Current oncology (Toronto, Ont.)
Published: July 03, 2025
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 13, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 05, 2024
Last Updated: 09/26/2026